1. Home
  2. SYRE vs ABCL Comparison

SYRE vs ABCL Comparison

Compare SYRE & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYRE
  • ABCL
  • Stock Information
  • Founded
  • SYRE 2013
  • ABCL 2012
  • Country
  • SYRE United States
  • ABCL Canada
  • Employees
  • SYRE N/A
  • ABCL N/A
  • Industry
  • SYRE Biotechnology: Pharmaceutical Preparations
  • ABCL Biotechnology: Pharmaceutical Preparations
  • Sector
  • SYRE Health Care
  • ABCL Health Care
  • Exchange
  • SYRE Nasdaq
  • ABCL Nasdaq
  • Market Cap
  • SYRE 1.1B
  • ABCL 1.1B
  • IPO Year
  • SYRE 2016
  • ABCL 2020
  • Fundamental
  • Price
  • SYRE $16.26
  • ABCL $4.24
  • Analyst Decision
  • SYRE Buy
  • ABCL Strong Buy
  • Analyst Count
  • SYRE 5
  • ABCL 5
  • Target Price
  • SYRE $55.00
  • ABCL $8.75
  • AVG Volume (30 Days)
  • SYRE 545.5K
  • ABCL 6.7M
  • Earning Date
  • SYRE 08-06-2025
  • ABCL 08-07-2025
  • Dividend Yield
  • SYRE N/A
  • ABCL N/A
  • EPS Growth
  • SYRE N/A
  • ABCL N/A
  • EPS
  • SYRE N/A
  • ABCL N/A
  • Revenue
  • SYRE N/A
  • ABCL $23,114,000.00
  • Revenue This Year
  • SYRE N/A
  • ABCL N/A
  • Revenue Next Year
  • SYRE N/A
  • ABCL $71.11
  • P/E Ratio
  • SYRE N/A
  • ABCL N/A
  • Revenue Growth
  • SYRE N/A
  • ABCL N/A
  • 52 Week Low
  • SYRE $10.91
  • ABCL $1.89
  • 52 Week High
  • SYRE $40.26
  • ABCL $5.82
  • Technical
  • Relative Strength Index (RSI)
  • SYRE 48.34
  • ABCL 50.27
  • Support Level
  • SYRE $16.43
  • ABCL $4.67
  • Resistance Level
  • SYRE $17.70
  • ABCL $5.19
  • Average True Range (ATR)
  • SYRE 0.99
  • ABCL 0.40
  • MACD
  • SYRE -0.02
  • ABCL -0.09
  • Stochastic Oscillator
  • SYRE 37.17
  • ABCL 18.97

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Share on Social Networks: